Equity Details
Price & Market Data
Price: $4.28
Daily Change: +$0.14 / 3.27%
Daily Range: $4.06 - $4.29
Market Cap: $304,677,600
Daily Volume: 435,614
Performance Metrics
1 Week: 4.65%
1 Month: -23.02%
3 Months: 78.33%
6 Months: 234.4%
1 Year: 231.8%
YTD: 217.0%
About Zentalis Pharmaceuticals, Inc. (ZNTL)
Get the latest on Zentalis Pharmaceuticals, Inc. (ZNTL). Priced at 4.28, with a daily shift of +$0.14 / 3.27%. Market cap: 304,677,600. Crucial performance data includes YTD (217.0%) and 1-month (-23.02%) returns.
Company Details
Employees: 106
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.